Experimental CAR T-Cell therapy targets tough lymphoma cases
Disease control
Terminated
This early-stage study tested a new treatment called ATA3219 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that had come back or stopped responding to other treatments. The therapy uses specially engineered immune cells from a healthy donor to attack cancer…
Phase: PHASE1 • Sponsor: Atara Biotherapeutics • Aim: Disease control
Last updated May 17, 2026 10:39 UTC